Bone marrow-derived mesenchymal stem cells increase dopamine synthesis in the injured striatum

doi:10.3969/j.issn.1673-5374.2012.34.002

Abstract

Abstract:

Previous studies showed that tyrosine hydroxylase or neurturin gene-modified cells transplanted into rats with Parkinson’s disease significantly improved behavior and increased striatal dopamine content. In the present study, we transplanted tyrosine hydroxylase and neurturin gene-modified bone marrow-derived mesenchymal stem cells into the damaged striatum of Parkinson’s disease model rats. Several weeks after cell transplantation, in addition to an improvement of motor function, tyrosine hydroxylase and neurturin proteins were up-regulated in the injured striatum, and importantly, levels of dopamine and its metabolite 3,4-dihydroxyphenylacetic acid increased significantly. Furthermore, the density of the D2 dopamine receptor in the postsynaptic membranes of dopaminergic neurons was decreased. These results indicate that transplantation of tyrosine hydroxylase and neurturin gene-modified bone marrow-derived mesenchymal stem cells increases dopamine synthesis and significantly improves the behavior of rats with Parkinson’s disease.

Key words: Parkinson’s disease, tyrosine hydroxylase, neurturin, bone marrow-derived mesenchymal stem cells, transplantation, dopamine, gene therapy, neurodegenerative disease, regeneration, neural

Yue Huang, Cheng Chang, Jiewen Zhang, Xiaoqun Gao. Bone marrow-derived mesenchymal stem cells increase dopamine synthesis in the injured striatum[J]. Neural Regeneration Research, 2012, 7(34): 2653-2662.

References

[1] de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5(6):525-535.

[2] Park NH. Parkinson disease. JAAPA. 2012;25(5):73-74.

[3] Balarajah S, Cavanna AE. The pathophysiology of impulse control disorders in Parkinson disease. Behav Neurol. in press.

[4] Katsuki H, Michinaga S. Anti-Parkinson drugs and orexin neurons. Vitam Horm. 2012;89:279-290.

[5] Zheng KS, Dorfman BJ, Christos PJ, et al. Clinical characteristics of exacerbations in Parkinson disease. Neurologist. 2012;18(3):120-124.

[6] Liang W, Cai Q, Liu Y. Transfection of human vascular endothelial growth factor 165 gene into rat bone marrow mesenchymal stem cells in vitro. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2011;25(11):1383-1388.

[7] Zanini C, Bruno S, Mandili G, et al. Differentiation of mesenchymal stem cells derived from pancreatic islets and bone marrow into islet-like cell phenotype. PLoS One. 2011;6(12):e28175.

[8] Wislet-Gendebien S, Laudet E, Neirinckx V, et al. Adult bone marrow: which stem cells for cellular therapy protocols in neurodegenerative disorders? J Biomed Biotechnol. 2012;2012:601560.

[9] Dezawa M, Kanno H, Hoshino M, et al. Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J Clin Invest. 2004;113(12):1701-1710.

[10] Pourrajab F, Forouzannia SK, Tabatabaee SA. Molecular characteristics of bone marrow mesenchymal stem cells, source of regenerative medicine. Int J Cardiol. in press.

[11] Kamal MA. Editorial: Status of tyrosine hydroxylase in the healthy and Parkinson's brain. CNS Neurol Disord Drug Targets. 2012;11(4):336-339.

[12] Tolleson C, Claassen D. The function of tyrosine hydroxylase in the normal and Parkinsonian brain. CNS Neurol Disord Drug Targets. 2012;11(4):381-386.

[13] Wang ZH, Ji Y, Shan W, et al. Therapeutic effects of astrocytes expressing both tyrosine hydroxylase and brain-derived neurotrophic factor on a rat model of Parkinson’s disease. Neuroscience. 2002;113(3):629-640.

[14] Bespalov MM, Sidorova YA, Tumova S, et al. Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin. J Cell Biol. 2011; 192(1):153-169.

[15] Kotzbauer PT, Lampe PA, Heuckeroth RO, et al. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature. 1996;384(6608):467-470.

[16] Tanriover G, Seval-Celik Y, Ozsoy O, et al. The effects of docosahexaenoic acid on glial derived neurotrophic factor and neurturin in bilateral rat model of Parkinson’s disease. Folia Histochem Cytobiol. 2010;48(3):434-441.

[17] Gasmi M, Herzog CD, Brandon EP, et al. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther. 2007;15(1):62-68.

[18] Bartus RT, Brown L, Wilson A, et al. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis. 2011;44(1):38-52.

[19] Ye M, Wang XJ, Zhang YH, et al. Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson's disease. Brain Res. 2007;1142: 206-216.

[20] Herzog CD, Dass B, Gasmi M, et al. Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Mol Ther. 2008;16(10):1737-1744.

[21] Gao J, Nalls MA, Shi M, et al. An exploratory analysis on gene-environment interactions for Parkinson disease. Neurobiol Aging. 2012;33(10):2528.e1-6.

[22] Dumitriu A, Latourelle JC, Hadzi TC, et al. Gene expression profiles in Parkinson disease prefrontal cortex implicate FOXO1 and genes under its transcriptional regulation. PLoS Genet. 2012;8(6):e1002794.

[23] Russell JA, Ciucci MR, Hammer MJ, et al. Videofluorographic assessment of deglutitive behaviors in a rat model of aging and parkinson disease. Dysphagia. in press.

[24] García J, Carlsson T, Döbrössy M, et al. Impact of dopamine versus serotonin cell transplantation for the development of graft-induced dyskinesia in a rat Parkinson model. Brain Res. 2012;1470:119-129.

[25] Soler R, Füllhase C, Hanson A, et al. Stem cell therapy ameliorates bladder dysfunction in an animal model of Parkinson disease. J Urol. 2012;187(4):1491-1497.

[26] Dabbeni-Sala F, Di Santo S, Franceschini D, et al. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J. 2001;15(1):164-170.

[27] Mansouri Z, Sabetkasaei M, Moradi F, et al. Curcumin has neuroprotection effect on homocysteine rat model of parkinson. J Mol Neurosci. 2012;47(2):234-242.

[28] Panneton WM, Kumar VB, Gan Q, et al. The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis. PLoS One. 2010;5(12):e15251.

[29] Dalpiaz A, Cacciari B, Vicentini CB, et al. A novel conjugated agent between dopamine and an A2A adenosine receptor antagonist as a potential anti-Parkinson multitarget approach. Mol Pharm. 2012;9(3):591-604.

[30] Hurley MJ, Jenner P. What has been learnt from study of dopamine receptors in Parkinson's disease? Pharmacol Ther. 2006;111(3):715-728.

[31] González-Hernández T, Cruz-Muros I, Afonso-Oramas D, et al. Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease. Front Neuroanat. 2010;4:140.

[32] The Ministry of Science and Technology of the People’s Republic of China. Guidance Suggestions for the Care and Use of Laboratory Animals. 2006-09-30.

[33] Li H, Daculsi R, Grellier M, et al. The role of vascular actors in two dimensional dialogue of human bone marrow stromal cell and endothelial cell for inducing self-assembled network. PLoS One. 2011;6(2):e16767.

[34] Bhavsar D, Trivedi J, Parekh S, et al. Synthesis and in vitro anti-HIV activity of N-1,3-benzo[d]thiazol-2-yl-2- (2-oxo-2H-chromen-4-yl)acetamide derivatives using MTT method. Bioorg Med Chem Lett. 2011;21(11):3443-3446.

[35] Pruszak J, Ludwig W, Blak A, et al. CD15, CD24, and CD29 define a surface biomarker code for neural lineage differentiation of stem cells. Stem Cells. 2009;27(12): 2928-2940.

[36] Gutensohn K, Nikolitsis A, Gramatzki M, et al. Direct volumetric flow cytometric quantitation of CD34+ stem and progenitor cells. Transfus Med. 2012;22(3):205-210.

[37] Bookout AL, Mangelsdorf DJ. Quantitative real-time PCR protocol for analysis of nuclear receptor signaling pathways. Nucl Recept Signal. 2003;1:e012.

[38] Palmieri M, Vagnini M, Pitzurra L, et al. Development of an analytical protocol for a fast, sensitive and specific protein recognition in paintings by enzyme-linked immunosorbent assay (ELISA). Anal Bioanal Chem. 2011;399(9): 3011-3023.

[39] Blum D, Torch S, Lambeng N, et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol. 2001;65(2):135-172.

[40] Choudhary RK, Daniels KM, Evock-Clover CM, et al. Technical note: A rapid method for 5-bromo-2'- deoxyuridine (BrdU) immunostaining in bovine mammary cryosections that retains RNA quality. J Dairy Sci. 2010; 93(6):2574-2579.

[41] Ge S, Woo E, White JG, et al. Electrochemical measurement of endogenous serotonin release from human blood platelets. Anal Chem. 2011;83(7): 2598-2604.

[42] Bergersen LH, Storm-Mathisen J, Gundersen V. Immunogold quantification of amino acids and proteins in complex subcellular compartments. Nat Protoc. 2008;3(1): 144-152.